AbbVie Remains Confident About Rinvoq Despite Coming Safety Labeling Update

A safety-related FDA revision of Rinvoq’s label in rheumatoid arthritis is a perceived threat to the JAK inhibitor’s growth, but it and fellow immunology asset Skyrizi produced another strong sales quarter.